Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 137 clinical trials
featured
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

  • 332 views
  • 08 Nov, 2020
  • 1 location
featured
Do You Have Osteoporosis?

Do You Have Osteoporosis?

  • 1122 views
  • 08 Nov, 2020
  • 1 location
Management of Low-risk DCIS

A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-grade DCIS. This implies that many women might be unnecessarily going through

cancer
breast cancer
invasive breast cancer
hormone therapy
mastectomy
  • 410 views
  • 08 Nov, 2020
  • 1 location
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

carcinoma in situ (DCIS) patients, the aforementioned two studies included a proportional patients who had young age and negative estrogen receptor (ER) status tumor. Previous studies and our studies

breast cancer
estrogen
carcinoma in situ
mammogram
estrogen receptor
  • 9 views
  • 12 Aug, 2019
  • 1 location
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in

core needle biopsy
carcinoma in situ
mammogram
neutrophil count
  • 46 views
  • 07 Nov, 2020
  • 2 locations
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast

Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in

estrogen
lobular carcinoma in situ
progesterone receptor
cancer
progesterone
  • 15 views
  • 02 Aug, 2020
  • 13 locations
Neoadjuvant Multi-epitope HER2 Peptide Vaccine in Patients With HER2-expressing DCIS

carcinoma in situ (DCIS). The ultimate goal of this vaccine is to prevent future invasive breast cancer among patients who are diagnosed with DCIS. However, the focus of this study is safety and efficacy

tetanus
breast cancer
hormone therapy
HER2
carcinoma in situ
  • 20 views
  • 10 Jun, 2019
  • 2 locations
Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

the side effects of doxorubicin hydrochloride liposome and to see how well it works in treating women with ductal carcinoma in situ undergoing surgery.

ductal carcinoma
doxorubicin
tumor cells
carcinoma in situ
ductal carcinoma in situ
  • 0 views
  • 07 Nov, 2020
  • 1 location
Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer

Whether the patients with low grade ductal carcinoma in situ breast cancer should accept radiationtherapy is uncertain.Radiation therapy uses high-energy x-rays to damage tumor cells. Giving

ductal carcinoma
breast cancer
tumor cells
carcinoma in situ
ductal carcinoma in situ
  • 0 views
  • 08 Nov, 2020
Comparing an Operation to Monitoring With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferior cancer or quality of life outcomes compared to surgery.

breast cancer
hormone therapy
invasive cancer
HER2
carcinoma in situ
  • 1205 views
  • 28 Nov, 2020
  • 133 locations